



Ain Shams University
Faculty of Science
Biochemistry Department



A one year study on the rate of HEV antibody seroconversion in different Egyptian governorates

A thesis submitted for partial fulfillment for the
master degree of Biochemistry

By

Sameh Safwat Salama

Supervised by

Prof. Dr.

Nadia Y. S. Morcos

Professor of Biochemistry
Faculty of Science
Ain Shams University

Prof. Dr.

Amina Mohamed Medhat

Professor of Biochemistry
Faculty of Science
Ain Shams University

Dr.

Emad William Mohareb

Head of Virology Research Program
NAMRU-3

2011

***I declare that this thesis has been composed by myself
and the work there in has not been submitted for a
degree at this or any other universities.***

Sameh Safwat Salama



جامعة عين شمس
كلية العلوم
قسم الكيمياء الحيوية



دراسة معدل التحول السيروولوجي للأجسام المضادة لفيروس الإلتهاب الكبدي الوبائي (هـ) خلال عام في محافظات مصرية مختلفة

رسالة مقدمة للحصول على درجة الماجستير
مقدمة من

سامح صفوت سلامة

تحت إشراف

أ.د/ نادية يوسف صادق	أ.د/ أمينة محمد مدحت
مقرس	أستاذ الكيمياء الحيوية
أستاذ الكيمياء الحيوية	كلية العلوم- جامعة عين شمس
كلية العلوم- جامعة عين شمس	

د./ عماد وليم محارب

رئيس قسم الفيروسات

وحدة الأبحاث الطبية البحرية الأمريكية رقم 3

2011

BIOGRAPHY

Name : Sameh Safwat Salama Mansour

Date and Place of birth: 23/11/1973, Cairo-Egypt

Name of Institute : Ain Shams university-Faculty of Science

Degree awarded : B.Sc in Biochemistry (1995)

Grade : Very Good with Honor degree

Name of Institute : Faculty of Pharmacy-Cairo University

Degree awarded : Diploma in biochemical analysis (1998)

Grade : Very Good

Name of Institute : University of IOWA-School of Public Health-USA

Degree awarded : Certificate on emerging infectious diseases epidemiology (2009)

Grade : Excellent

Acknowledgement

*Foremost, I would like to express my sincere gratitude to my advisor **Prof. Nadia Y.S. Morcos**, Professor of Biochemistry, Faculty of science, Ain Shams University for the continuous support during the study and research, for her patience, motivation, enthusiasm, and immense knowledge.*

*I am deeply grateful to **Dr. Amina Medhat**, Professor of Biochemistry, Faculty of science, Ain Shams University. Her guidance helped me in all the time of research and writing of this thesis.*

*My sincere thanks also goes to **Dr. Emad William Mohareb**, Head of Viral and zoonotic diseases Research program, NAMRU-3 for enlightening me the first glance of research, for his detailed and constructive comments, and for his important support throughout this work,*

I could not have imagined having better advisors for my Master study.

I would like to thank labmates in serology and field studies unit for their hard working during the collection and testing of samples.

Last but not the least, I would like to thank my family: my parents and in particular my wife. They were supporting me spiritually throughout my life.

LIST OF CONTENTS

	Page
List of Abbreviations.....	iv
List of Tables	v
List of Figures.....	viii
Abstract.....	xi
Introduction.....	xiii
Aim of the work.....	xv
I. Review of literature	1
1.1. History.....	1
1.2. Virus.....	2
1.2.1 Morphology and genomic organization	2
1.2.2. Classification of HEV	8
1.3. Geographic Distribution and Genetic Variation	9
1.4. Antigenic Composition	13
1.5. Epidemiology	15
1.5.1. Hepatitis E in highly disease-endemic regions ...	17
1.5.2. Hepatitis E in regions where disease is infrequent	19
1.5.3. Anti-HEV seroprevalence data.....	20
1.5.4. HEV in Egypt	21
1.6. Modes of Transmission.....	23
1.7. Host Range, Experimental Transmission to Animals.....	24
1.8. Pathogenesis	28
1.8.1. Incubation Period	28
1.8.2. Viral Replication	29
1.8.3. Pathology	31
1.9. Immune Response	33
1.10. Hepatitis E and Pregnancy	34
1.10.1. Immunological changes during pregnancy	36
1.10.2. Hormonal Factors in Pregnancy	37
1.11. Clinical Manifestations	38

1.11.1. Symptoms	38
1.11.2. Complications	39
1.12. Laboratory Diagnosis	39
1.12.1. Serologic Tests	40
1.12.2. Molecular Tests	42
1.13. Immunity	43
1.14. Prevention	43
1.14.1. General Sanitation.....	43
1.14.2. Immunoprophylaxis	44
1.15. Therapy	46
1.16. Hepatitis in Egypt	46
1.16.1. Hepatitis A Virus (HAV)	46
1.16.1.1. HAV Viral genome	47
1.16.1.2. HAV in Egypt	48
1.16.2. Hepatitis B Virus (HBV).....	48
1.16.2.1. HBV Viral Genome.....	49
1.16.2.2. HBV in Egypt.....	50
1.16.3. Hepatitis C Virus (HCV).....	51
1.16.3.1. HCV Viral Genome	52
1.16.3.2. HCV in Egypt	53
II. Subjects and Methods	55
2.1. Study Design	55
2.2. Subjects	55
2.2.1 Study sites	55
2.2.2. Selection of families for the cohort	56
2.2.2.1 Inclusion criteria	56
2.2.2.2. Exclusion criteria.....	56
2.2.3. Donation form for biological material	56
2.3. Methods	57
2.3.1. Viral Markers.....	57
2.3.1.1. Anti-HEV-IgG	57
2.3.1.1.1 Principle	57
2.3.1.1.2 Calculation	58
2.3.1.2. Anti-HAV	58
2.3.1.2.1. Principle	58
2.3.1.2.2. Calculation	59

2.3.1.3 Anti-HBc monoclonal	59
2.3.1.3.1 Principle	59
2.3.1.3.2 Calculation	60
2.3.1.4. Enzygnost HBsAg 5.0.....	60
2.3.1.4.1. Principle	60
2.3.1.4.2. Calculation	61
2.3.1.5. Anti- HCV 3.0.....	61
2.3.1.5.1 Principle	61
2.3.1.5.2. Calculation	62
2.3.2. Liver function Tests	63
2.3.2.1. Alanine transaminase (ALT).....	63
2.3.2.1.1. Principle	63
2.3.2.1.2. Reference Range	63
2.3.2.2. Aspartate aminotransferase(AST)	63
2.3.2.2.1. Principle	63
2.3.2.2.2. Reference Range	64
2.3.2.3.Total Bilirubin.....	64
2.3.2.3.1. Principle	64
2.3.2.3.2. Reference Range	64
2.3.3. Kidney function tests.....	64
2.3.3.1. Determination of Urea in sera	64
2.3.3.1.1. Principle	64
2.3.3.1.2. Reference range	65
2.3.3.2 .Determination of Creatinine in sera	65
2.3.3.2.1. Principle	65
2.3.3.2.2. Reference Range	65
2.4. Statistical analysis.....	65
III. Results	66
IV. Discussion	141
V. Summary	162
VI. Conclusion and Recommendations	165
VII. References	167
VIII. Appendix	200
X. Arabic Abstract	-
XI. Arabic summary	-

LIST OF ABBREVIATIONS

AA	Amino Acid
ALT	Alanine Aminotransferase
AST	Aspartate Aminotransferase
CMV	Cytomegalovirus
CRE	cis-reactive element
ELISA	Enzyme-linked immunosorbent assay
HAV	Hepatitis A virus
HBcAb	Hepatitis B core Antibody
HBsAg	Hepatitis B Surface Antigen
HBV	Hepatitis B virus
HCG	Human chorionic gonadotropin
HCV	Hepatitis C virus
HEV	Hepatitis E Virus
HLA	Human Leukocyte Antigen
IgG	Immunoglobulin G
IgM	Immunoglobulin M
Mabs	Monoclonal antibodies
MHC	Major Histocompatibility Complex
mRNA	Messenger RNA
NK)	Natural Killer cells
NPV	Negative predictive value
ORFs	Open reading frames
PAT	Parenteral antischistosomal therapy
PCP	Papain-like cysteine protease
PCR	Polymerase chain reaction
PPV	Positive predictive value
RDRP	RNA-dependent RNA polymerase
RT-PCR	Reverse transcriptase-polymerase chain reaction
SVPs	Subviral particles
UTRs	Untranslated regions
VLPs	Virus-like particles

LIST OF TABLES

Table no.	Page no.
(3.1) Distribution of first & second samples taken from the three governates	66
(3.2) Demographic distribution of participants (1 st sample) among the three governates	68
(3.3) Demographic distribution of participants (2 nd sample) among the three governates	70
(3.4) Statistical differences for HEV seroprevalence in 1 st samples among the three governates (χ^2)	72
(3.5) Statistical differences for HEV new infection (2 nd samples) among the three governates (χ^2)	74
(3.6) HEV 1 st sample prevalence among different age groups	77
(3.7) HEV 2 nd sample prevalence among different age groups	77
(3.8) HEV seroprevalence in 1 st samples in different age groups among the three governates (χ^2)	79
(3.9) Statistical differences for HEV seroprevalence in 2 nd samples according to age among the three governates (χ^2)	81
(3.10) Statistical differences for HEV infection in both samples according to gender (χ^2)	83
(3.11) Statistical differences for HEV seroprevalence (in 1 st sample) according to gender in the 3 governates (χ^2)	84
(3.12) Statistical differences for HEV new infection (in 2 nd sample) according to gender in the 3 governates (χ^2)	85
(3.13) Distribution of HEV incidence in each age group in both genders for ALL participants (both samples)	86
(3.14) Distribution of HEV incidence in each age group in both genders in FAIYUM (both samples)	88
(3.15) Distribution of HEV incidence in each age group in both genders in QENA (both samples)	89
(3.16) Distribution of HEV incidence in each age group in both genders in ZAGAZIG (both samples)	90
(3.17a) Seroprevalence of HEV in the 1 st sample in both genders in each age group for the 3 governates	93

Table no.	Page no.
(3.17b) Seroprevalence of HEV in the 2 nd sample in both genders in each age group for the 3 governates.....	94
(3.18) Seroprevalence of HBcAb, HBsAg, and HCV in the 3 governates.....	95
(3.19a) Statistical differences for HBcAb seroprevalence in samples according to age among the three governates (χ^2)	97
(3.19b) Statistical differences for HBsAg seroprevalence in samples according to age among the three governates (χ^2)	98
(3.20) Statistical differences for HCV seroprevalence in samples according to age among the three governates (χ^2)	100
(3.21) % Seroprevalence of HBcAb, HBsAg, and HCV among each age group for both genders	101
(3.22) Seroprevalence of HEV in presence of other viruses	104
(3.23) Seroprevalence of HEV in presence of HBcAb among the 3 governates.....	106
(3.24) Seroprevalence of HEV in presence of HBsAg among the 3 governates.....	107
(3.25) Seroprevalence of HEV in presence of HCV among the 3 governates.....	108
(3.26) Spearman's correlation between viruses, age and gender for ALL participants.....	112
(3.27) Spearman's correlation between viruses, age and gender in FAIYUM	113
(3.28) Spearman's correlation between viruses, age and gender in QENA.....	114
(3.29) Spearman's correlation between viruses, age and gender in ZAGAZIG	115
(3.30) Effect of family members on viral infection in all participants	116
(3.31) Effect of family members on HEV viral infection in different governates.....	118
(3.32) Effect of family members on HBV viral infection in different governates.....	120

Table no.	Page no.
(3.33) Effect of family members on HCV viral infection in different governates.....	122
(3.34) Effect of drinking water source on viral infection in all participants	123
(3.35) Effect of washing water source on viral infection in all participants	125
(3.36) Effect of in-house animals on viral infection in all participants	127
(3.37) Levels of biochemical parameters according to viral infections	129
(3.38) Levels of biochemical parameters, BUN and creatinine according to age	132
(3.39) Levels of biochemical parameters according to age in HCV –ve participants.....	134
(3.40) Paired t-test for changes in biochemical parameters due to recent HEV infection (no other viral infections)	136
(3.41) Cross tabulation for the calculated cut-off values of ALT and AST.....	140

LIST OF FIGURES

Fig. no.	Page no.
(1.1) Hepatitis E Virus.....	3
(1.2) Structure of the hepatitis E virus-like particle (VLP)	4
(1.3) Genome organization and major antigenic domains of HEV	5
(1.4) Role of the ORF3 protein in HEV pathogenesis	7
(1.5) HEV endemic areas and global seroprevalence.....	9
(1.6) HEV and its genotypes.....	12
(1.7) Antigenic composition of HEV genome	14
(1.8) World map showing regions where hepatitis E is highly endemic	17
(1.9) Putative replication cycle of hepatitis E virus	30
(1.10) Diagram of clinical and serological events in a typical case of acute hepatitis E.	41
(1.11) Hepatitis A Virus genome	48
(1.12) Diagrammatic structure of HBV particle.	49
(1.13) Hepatitis B virus genome organization map	50
(1.14) Diagrammatic structure of HCV particle	52
(1.15) Hepatitis C Virus genome	53
(3.1) Distribution of samples among the three governates	67
(3.2a) Gender distribution between participants (1 st sample) in the three governates	69
(3.2b) Age distribution between participants (1 st sample) in the three governates	69
(3.3a) Gender distribution between participants (2 nd sample) in the three governates	71
(3.3b) Age distribution between participants (2 nd sample) in the three governates	71
(3.4a) % Seroprevalence of HEV in 1 st samples among the three governates.....	72
(3.4b) % Seroprevalence of HEV in 1 st samples among the three governates.....	73
(3.5a) Prevalence of HEV infection in 2 nd samples among the three governates	74
(3.5b) % Prevalence of HEV infection in 2 nd samples among the three governates	75
(3.6) Distribution of HEV 1 st sample seroprevalence within different age groups in all participants.....	77

Fig. no.	Page no.
(3.7) Distribution of HEV 2 nd sample seroprevalence in different age groups in all participants.....	78
(3.8) Distribution of HEV 1 st sample seroprevalence in each age group among the three governates.....	80
(3.9) Distribution of HEV 2 nd sample seroprevalence in each age group among the three governates.....	82
(3.10) HEV seroprevalence in both samples according to gender.....	83
(3.11) HEV distribution in 1 st sample according to gender in the 3 governates.....	84
(3.12) HEV distribution in 2 nd sample according to gender in the 3 governates.....	85
(3.13a) % Seroprevalence of HEV in the 1 st sample in both genders in each age group	87
(3.13b) % Seroprevalence of HEV in the 2 nd sample in both genders in each age group	87
(3.14 a-c) % Seroprevalence of HEV in the 1 st sample in both genders in each age group for the 3 governates.....	91
(3.15 a-c) % Seroprevalence of HEV in the 2 nd sample in both genders in each age group for the 3 governates.....	92
(3.16) % Seroprevalence of HBV (HBcAb & HBsAg) and HCV in each governate	96
(3.17) % HBcAb prevalence in samples according to age among the three governates	99
(3.18) HBsAg prevalence in samples according to age among the three governates	99
(3.19) HCV seroprevalence in samples according to age among the three governates	101
(3.20a) % Seroprevalence of HBcAb among each age group for both genders.....	102
(3.20b) % Seroprevalence of HBsAg among each age group for both genders.....	102
(3.20c) % Seroprevalence of HBcAb among each age group for both genders.....	103
(3.21) % Seroprevalence of HBcAb among each age group for both genders	
(3.22) % HEV seroprevalence in presence of other viruses	105
(3.23-24a) % Seroprevalence of HEV (2 samples) with other viruses in different governates.....	109
(3.23-24b) % Seroprevalence of HEV (2 samples) with other viruses	

Fig. no.	Page no.
24b) in different governates.....	111
(3.25a – % Seroprevalence of all viruses in different categories of	
3.25b) family members	117
(3.26- Effect of number of family members & HEV infection	
3.27) during first and second samples.....	119
(3.28- Effect of number of family members & HBV	
3.29) infection.....	121
(3.30) Effect of number of family members & HCV infection	122
(3.31) Effect of drinking water source on viral infection in all	
participants	124
(3.32) Effect of washing water source on viral infection in all	
participants	126
(3.33) Effect of in-house animals on viral infection in all	
participants	128
(3.34) Biochemical markers and number of infections	130
(3.35) Changes in biochemical parameters with age.....	133
(3.36) Changes in biochemical parameters with age in	
participants without HCV.....	135
(3.37) Changes in biochemical parameters after HEV infection	
(no other viral infections)	137
(3.38) ROC curve with the area under curve (AUC), sensitivity%	
and specificity% of the calculated cut-off value for ALT.....	138
(3.39) ROC curve with the area under curve (AUC), sensitivity%	
and specificity% of the calculated cut-off value for AST	139